4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 113 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2023. The put-call ratio across all filers is 2.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $525 | -34.1% | 25,000 | 0.0% | 0.22% | -33.3% |
| Q1 2024 | $797 | +57.2% | 25,000 | 0.0% | 0.32% | +47.3% |
| Q4 2023 | $507 | +59.4% | 25,000 | 0.0% | 0.22% | +49.7% |
| Q3 2023 | $318 | +15.6% | 25,000 | +56.2% | 0.15% | +16.7% |
| Q1 2023 | $275 | -66.5% | 16,000 | -56.8% | 0.13% | -68.2% |
| Q4 2022 | $822 | -99.8% | 37,000 | -27.5% | 0.40% | +85.9% |
| Q3 2022 | $410,000 | +91.6% | 51,000 | +66.6% | 0.21% | +104.8% |
| Q2 2022 | $214,000 | – | 30,614 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 4,400,000 | $92,356,000 | 5.88% |
| Deep Track Capital, LP | 4,061,401 | $85,248,807 | 2.54% |
| BVF INC/IL | 3,922,413 | $82,331,449 | 2.31% |
| Decheng Capital LLC | 347,835 | $7,301,057 | 2.24% |
| Novo Holdings A/S | 1,400,000 | $29,386,000 | 1.71% |
| Eagle Health Investments LP | 462,911 | $9,716,502 | 1.70% |
| Opaleye Management Inc. | 345,750 | $7,257,293 | 1.66% |
| RA Capital Management | 5,098,211 | $107,011,449 | 1.42% |
| Redmile Group, LLC | 1,073,435 | $22,531,401 | 1.36% |
| Casdin Capital, LLC | 800,000 | $16,792,000 | 1.29% |